The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
aloxistatin inhibits the reaction [CAPN1 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]
aloxistatin inhibits the reaction [CAPN7 protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]
[aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein] [Swainsonine co-treated with aloxistatin] results in increased cleavage of CASP3 protein
[aloxistatin co-treated with pepstatin] results in decreased expression of CTSB protein; aloxistatin inhibits the reaction [CTSB protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]
aloxistatin inhibits the reaction [CTSL protein results in increased degradation of and results in decreased expression of SMN2 protein alternative form]
[aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [ABTL0812 results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [Brefeldin A results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] promotes the reaction [N-((1R,2S)-2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl)octanamide results in increased expression of and results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in decreased degradation of MAP1LC3B protein modified form; aloxistatin promotes the reaction [indatraline results in increased lipidation of MAP1LC3B protein] aloxistatin results in increased lipidation of MAP1LC3B protein [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Biological Factors deficiency results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased degradation of MAP1LC3B protein modified form]; [aloxistatin co-treated with pepstatin] inhibits the reaction [Dronabinol results in increased lipidation of MAP1LC3B protein]; [aloxistatin co-treated with pepstatin] results in increased expression of MAP1LC3B protein
[aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; aloxistatin promotes the reaction [indatraline results in increased expression of SQSTM1 protein]; aloxistatin promotes the reaction [Sertraline results in increased expression of SQSTM1 protein] aloxistatin results in increased expression of SQSTM1 protein [aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [Dronabinol co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein; [HU 211 co-treated with aloxistatin co-treated with pepstatin] results in increased expression of SQSTM1 protein
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein] 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]]; amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]]; amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]
amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CD36 mRNA]; amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CD36 protein]; CD36 protein inhibits the reaction [amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of PPARG protein]]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]]; amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]]; amentoflavone inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased phosphorylation of MAPK3 protein]
amentoflavone results in decreased expression of NOS2 protein amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]
amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of PPARG protein]; CD36 protein inhibits the reaction [amentoflavone inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of PPARG protein]]
amentoflavone results in decreased expression of PTGS2 mRNA; amentoflavone results in decreased expression of PTGS2 protein [amentoflavone results in decreased expression of PTGS2 protein] which results in decreased chemical synthesis of Dinoprostone
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]
amentoflavone results in decreased activity of UGT1A6 protein amentoflavone inhibits the reaction [UGT1A6 protein results in increased glucuronidation of 4-cresol]
ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein] ginkgetin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]
ginkgetin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2 protein] ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]
leupeptin inhibits the reaction [xanthatin results in decreased stability of CDC25C protein] leupeptin results in increased expression of CDC25C protein
Fomepizole inhibits the reaction [leupeptin promotes the reaction [Acetaminophen results in increased activity of GPT protein]]; leupeptin promotes the reaction [Acetaminophen results in increased activity of GPT protein]
leupeptin inhibits the reaction [MT1A protein results in decreased expression of XAF1 protein]; leupeptin inhibits the reaction [XAF1 protein results in decreased expression of MT1A protein]
leupeptin inhibits the reaction [MT2A protein results in decreased expression of XAF1 protein]; leupeptin inhibits the reaction [XAF1 protein results in decreased expression of MT2A protein]
leupeptin inhibits the reaction [Nelfinavir results in increased degradation of PLIN1 protein] leupeptin results in decreased degradation of PLIN1 protein
leupeptin inhibits the reaction [MT1A protein results in decreased expression of XAF1 protein]; leupeptin inhibits the reaction [MT2A protein results in decreased expression of XAF1 protein]; leupeptin inhibits the reaction [XAF1 protein results in decreased expression of MT1A protein]; leupeptin inhibits the reaction [XAF1 protein results in decreased expression of MT2A protein]
sciadopitysin results in decreased activity of ABCB1 protein sciadopitysin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]
sciadopitysin results in increased expression of BGLAP protein sciadopitysin inhibits the reaction [Antimycin A results in increased expression of BGLAP protein]
browse the term
